In our aging society, with an increased urgency to develop new compounds that target serious illnesses like Alzheimer’s and Parkinson’s disease, memory enhancement drugs are becoming a big business. But these same drugs are also creating a growing ethical controversy over their potential off-label uses, such as taking these drugs as “performance enhancers” to gain a competitive advantage in the workplace.